S. Kuyumcu Et Al. , "Safety of Fibroblast Activation Protein-Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using Lu-177-FAPI04," CLINICAL NUCLEAR MEDICINE , vol.46, no.8, pp.641-646, 2021
Kuyumcu, S. Et Al. 2021. Safety of Fibroblast Activation Protein-Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using Lu-177-FAPI04. CLINICAL NUCLEAR MEDICINE , vol.46, no.8 , 641-646.
Kuyumcu, S., Kovan, B., Sanli, Y., Buyukkaya, F., Has Simsek, D., Özkan, Z. G., ... Isik, E. G.(2021). Safety of Fibroblast Activation Protein-Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using Lu-177-FAPI04. CLINICAL NUCLEAR MEDICINE , vol.46, no.8, 641-646.
Kuyumcu, Serkan Et Al. "Safety of Fibroblast Activation Protein-Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using Lu-177-FAPI04," CLINICAL NUCLEAR MEDICINE , vol.46, no.8, 641-646, 2021
Kuyumcu, Serkan Et Al. "Safety of Fibroblast Activation Protein-Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using Lu-177-FAPI04." CLINICAL NUCLEAR MEDICINE , vol.46, no.8, pp.641-646, 2021
Kuyumcu, S. Et Al. (2021) . "Safety of Fibroblast Activation Protein-Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using Lu-177-FAPI04." CLINICAL NUCLEAR MEDICINE , vol.46, no.8, pp.641-646.
@article{article, author={Serkan KUYUMCU Et Al. }, title={Safety of Fibroblast Activation Protein-Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using Lu-177-FAPI04}, journal={CLINICAL NUCLEAR MEDICINE}, year=2021, pages={641-646} }